Innovent Biologics (HKG:1801) unit Fortvita Biologics agreed to issue and sell 12,808,337 new series pre-A preferred shares to affiliate Lostrancos Ventures for $20.5 million, an Oct. 25 bourse filing said.
Following the completion of the issue, pharmaceutical firm Innovent Biologics' equity interest in Fortvita Biologics will be diluted to 80% from 100% previously.
Shares of the firm closed nearly 13% lower on Monday.
Price (HKD): $38.70, Change: $-5.6, Percent Change: -12.54%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments